Study Design
DesignRandomized, double-blind, placebo and active-controlled
Randomization2:1:2
BlindingDouble-blind
Enrollment837
Duration48 weeks
Treatment Arms
Guselkumab 100mg 100mg SC at Wk 0,4 then q8w n=329
Placebo → Guselkumab Placebo Wk 0-16, then guselkumab n=174
Adalimumab 40mg 80mg Wk 0, then 40mg q2w n=334
[{"id":"pasi90-w16","name":"PASI 90 at Week 16","type":"PRIMARY","unit":"%","results":[{"value":73.3,"arm_id":"gus-arm","p_value":0.001},{"value":49.7,"arm_id":"ada-arm"},{"value":2.9,"arm_id":"pbo-arm"}],"timepoint":"Week 16"}]